Biocept Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept or view top-rated stocks.

2 Wall Street research analysts have issued 12-month target prices for Biocept's stock. Their BIOC stock forecasts range from $4.00 to $4.00. On average, they predict Biocept's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price.
View analysts' price targets for Biocept or view top-rated stocks among Wall Street analysts.

Biocept's stock was trading at $3.62 at the beginning of 2022. Since then, BIOC stock has decreased by 75.1% and is now trading at $0.90.
View the best growth stocks for 2022 here.

Biocept saw a drop in short interest in May. As of May 31st, there was short interest totaling 243,600 shares, a drop of 16.2% from the May 15th total of 290,700 shares. Based on an average daily trading volume, of 103,900 shares, the short-interest ratio is presently 2.3 days.
View Biocept's Short Interest.

Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Biocept.

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, May, 23rd. The medical research company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The medical research company had revenue of $19.95 million for the quarter, compared to analysts' expectations of $6.99 million. Biocept had a negative net margin of 11.26% and a negative trailing twelve-month return on equity of 19.99%.
View Biocept's earnings history.

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Biocept include Sera Prognostics (SERA), Centogene (CNTG), Psychemedics (PMD), OpGen (OPGN), Vyant Bio (VYNT), PharmChem (PCHM), American Shared Hospital Services (AMS), CannLabs (CANL), CBA Florida (CBAI), Aclarion (ACON), Zicix (ZICX), AnPac Bio-Medical Science (ANPC), First Choice Healthcare Solutions (FCHS), PotNetwork (POTN) and Aeon Global Health (AGHC).
View all of BIOC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Biocept's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Acadian Asset Management LLC (0.16%), Taylor & Morgan Wealth Management LLC (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Biocept stock include David F Hale and David F Hale.
View institutional ownership trends for Biocept.

BIOC stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
View insider buying and selling activity for Biocept or view top insider-selling stocks.

BIOC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Taylor & Morgan Wealth Management LLC, and Group One Trading L.P..
View insider buying and selling activity for Biocept or or view top insider-buying stocks.

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $0.90.

Biocept (NASDAQ:BIOC) has a market capitalization of $15.23 million and generates $61.25 million in revenue each year. The medical research company earns $-2.82 million in net income (profit) each year or ($0.45) on an earnings per share basis.

Biocept employs 104 workers across the globe.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for Biocept is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.